The board of directors withdraws the proposal regarding a rights issue
As previously communicated, Greiner Bio-One GmbH ("GBO") owns more than 90 percent of the shares in Vigmed Holding AB (publ) ("Vigmed") and has requested compulsory redemption of the remaining shares in Vigmed.
GBO has informed Vigmed that GBO in view of GBO's initiation of compulsory redemption of the minority shares in Vigmed considers that the new share issue with preferential right for the company's shareholders proposed by the board of directors of Vigmed is no longer appropriate and that GBO will not vote in favor of the right issue at the contemplated extraordinary general meeting in Vigmed.
The board of directors of Vigmed concludes that the rights issue lacks sufficient support among the company's shareholders and has therefore resolved to withdraw its proposal regarding the rights issue.
For more information
CEO Henrik Olsen, tel. +46 763-497 364
Board member Georg Heftberger, tel. +43 664 884 106 83
This information was submitted for publication, through the agency of the contact persons set out above, at 8:15 a.m. CET on 6 July 2017.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on Nasdaq First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor